Evidence map›Paper›PMID 34152417›Full record

ArticleJAMA network open2021

Clinical Outcomes Following Acute Residential Psychiatric Treatment in Transgender and Gender Diverse Adolescents.

Marisa M Silveri, Eleanor M Schuttenberg, Kaya Schmandt, Elena R Stein, Maya M Rieselbach, Ariel Sternberg, Julia E Cohen-Gilbert, Sabra L Katz-Wise, Jennifer Urbano Blackford, Alexandra S Potter and 5 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Marisa M SilveriNeurodevelopmental Laboratory on Addictions and Mental Health, McLean Hospital, Belmont, Massachusetts.
Eleanor M SchuttenbergNeurodevelopmental Laboratory on Addictions and Mental Health, McLean Hospital, Belmont, Massachusetts.
Kaya SchmandtAdolescent Acute Residential Treatment Program, McLean Hospital, Belmont, Massachusetts.
Elena R SteinNeurodevelopmental Laboratory on Addictions and Mental Health, McLean Hospital, Belmont, Massachusetts.
Maya M RieselbachNeurodevelopmental Laboratory on Addictions and Mental Health, McLean Hospital, Belmont, Massachusetts.
Ariel SternbergAdolescent Acute Residential Treatment Program, McLean Hospital, Belmont, Massachusetts.
Julia E Cohen-GilbertNeurodevelopmental Laboratory on Addictions and Mental Health, McLean Hospital, Belmont, Massachusetts.
Sabra L Katz-WiseDivision of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts.
Jennifer Urbano BlackfordDepartment of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
Alexandra S PotterDepartment of Psychiatry, University of Vermont, Burlington, Vermont.
Mona P PotterMcLean Anxiety Mastery Program, McLean Hospital, Belmont, Massachusetts.
Dana B SarveyAdolescent Acute Residential Treatment Program, McLean Hospital, Belmont, Massachusetts.
Chad M McWhinnieAdolescent Acute Residential Treatment Program, McLean Hospital, Belmont, Massachusetts.
Jessica E FeinbergAdolescent Acute Residential Treatment Program, McLean Hospital, Belmont, Massachusetts.
Kathryn D BogerMcLean Anxiety Mastery Program, McLean Hospital, Belmont, Massachusetts.
McLean Hospital · USHarvard University · USBoston Children's Hospital · USUniversity of Vermont · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Transgender and gender diverse (TGD) individuals, who have a gender identity that differs from their sex assigned at birth, are at increased risk of mental health problems, including depression, anxiety, self-injurious behavior, and suicidality, relative to cisgender peers. Objective: To examine mental health outcomes among TGD vs cisgender adolescents in residential treatment. Design, Setting, and Participants: This cohort study's longitudinal design was used to compare groups at treatment entry and discharge, and 1-month postdischarge follow-up. The setting was an adolescent acute residential treatment program for psychiatric disorders. Participants were TGD or cisgender adolescents enrolled in the treatment program. Statistical analysis was performed October 2019 to March 2021. Exposure: Adolescents participated in a 2-week acute residential treatment program for psychiatric disorders. Main Outcomes and Measures: Primary outcomes were depressive (the Center for Epidemiologic Studies Depression Scale [CES-D]) and anxiety (the Multidimensional Anxiety Scale for Children [MASC]) symptoms, and emotional dysregulation (the Difficulties in Emotion Regulation Scale [DERS]), measured at treatment entry and discharge, and postdischarge follow-up. Age of depression onset, suicidality, self-injury, and childhood trauma also were assessed at treatment entry. Results: Of 200 adolescent participants who completed treatment entry and discharge assessments, the mean (SD) age was 16.2 (1.5) years; 109 reported being assigned female at birth (54.5%), 35 were TGD (17.5%), and 66 (49.3%) completed 1-month follow-up. TGD participants had an earlier mean (SD) age of depression onset (TGD: 10.8 [2.4] years vs cisgender: 11.9 [2.3] years; difference: 1.07 years; 95% CI, 0.14-2.01 years; P = .02), higher mean (SD) suicidality scores (TGD: 44.4 [23.1] vs cisgender: 28.5 [25.4]; difference: 16.0; 95% CI, 6.4-25.5; P = .001), more self-injurious behavior (mean [SD] RBQ-A score for TGD: 3.1 [2.5] vs cisgender: 1.7 [1.9]; difference: 1.42; 95% CI, 0.69-2.21; P = .001) and more childhood trauma (eg, mean [SD] CTQ-SF score for emotional abuse in TGD: 12.7 [5.4] vs cisgender: 9.8 [4.7]; difference: 2.85; 95% CI, 1.06-4.64; P = .002). The TGD group also had higher symptom scores (CES-D mean difference: 7.69; 95% CI, 3.30 to 12.08; P < .001; MASC mean difference: 7.56; 95% CI, 0.46 to 14.66; P = .04; and DERS mean difference: 18.43; 95% CI, 8.39 to 28.47; P < .001). Symptom scores were significantly higher at entry vs discharge (CES-D mean difference, -12.16; 95% CI, -14.50 to -9.80; P < .001; MASC mean difference: -3.79; 95% CI, -6.16 to -1.42; P = .02; and DERS mean difference: -6.37; 95% CI, -10.80 to -1.94; P = .05) and follow-up (CES-D mean difference: -9.69; 95% CI, -13.0 to -6.42; P < .001; MASC mean difference: -6.92; 95% CI, -10.25 to -3.59; P < .001; and DERS mean difference: -12.47; 95% CI, -18.68 to -6.26; P < .001). Conclusions and Relevance: This cohort study found mental health disparities in TGD youth relative to cisgender youth, with worse scores observed across assessment time points. For all participants, primary clinical outcome measures were significantly lower at treatment discharge than at entry, with no significant differences between discharge and 1-month follow-up. Given the substantial degree of mental health disparities reported in TGD individuals, these findings warrant focused clinical attention to optimize treatment outcomes in gender minority populations.

Indexed as

AdolescentAdolescent BehaviorFemaleHospitals, PsychiatricHumansMaleResidential TreatmentTransgender PersonsTreatment Outcome

Identifiers

PMID34152417
PMCPMC8218077
OpenAlexW3175184213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.